198 related articles for article (PubMed ID: 22520557)
1. Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro.
Latil A; Libon C; Templier M; Junquero D; Lantoine-Adam F; Nguyen T
BJU Int; 2012 Sep; 110(6 Pt B):E301-7. PubMed ID: 22520557
[TBL] [Abstract][Full Text] [Related]
2. Anti-inflammatory properties of Lipidosterolic extract of Serenoa repens (Permixon®) in a mouse model of prostate hyperplasia.
Bernichtein S; Pigat N; Camparo P; Latil A; Viltard M; Friedlander G; Goffin V
Prostate; 2015 May; 75(7):706-22. PubMed ID: 25683150
[TBL] [Abstract][Full Text] [Related]
3. Effects of hexanic extract of Serenoa repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia.
Latil A; Pétrissans MT; Rouquet J; Robert G; de la Taille A
Prostate; 2015 Dec; 75(16):1857-67. PubMed ID: 26306400
[TBL] [Abstract][Full Text] [Related]
4. Hexanic Extract of Serenoa repens (Permixon
Blair HA
Drugs Aging; 2022 Mar; 39(3):235-243. PubMed ID: 35237936
[TBL] [Abstract][Full Text] [Related]
5. Androgen-independent effects of Serenoa repens extract (Prostasan®) on prostatic epithelial cell proliferation and inflammation.
Iglesias-Gato D; Carsten T; Vesterlund M; Pousette A; Schoop R; Norstedt G
Phytother Res; 2012 Feb; 26(2):259-64. PubMed ID: 21656602
[TBL] [Abstract][Full Text] [Related]
6. Effect of the lipidosterolic extract of Serenoa repens (Permixon) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies.
Paubert-Braquet M; Cousse H; Raynaud JP; Mencia-Huerta JM; Braquet P
Eur Urol; 1998; 33(3):340-7. PubMed ID: 9555564
[TBL] [Abstract][Full Text] [Related]
7. Lipidosterolic extract of serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells.
Sirab N; Robert G; Fasolo V; Descazeaud A; Vacherot F; de la Taille A; Terry S
Int J Mol Sci; 2013 Jul; 14(7):14301-20. PubMed ID: 23846725
[TBL] [Abstract][Full Text] [Related]
8. Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia.
Plosker GL; Brogden RN
Drugs Aging; 1996 Nov; 9(5):379-95. PubMed ID: 8922564
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Hexanic Lipidosterolic Extract of Serenoa repens (Permixon) in the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Systematic Review and Meta-analysis of Randomized Controlled Trials.
Novara G; Giannarini G; Alcaraz A; Cózar-Olmo JM; Descazeaud A; Montorsi F; Ficarra V
Eur Urol Focus; 2016 Dec; 2(5):553-561. PubMed ID: 28723522
[TBL] [Abstract][Full Text] [Related]
10. Tumor necrosis factor-alpha up-regulates the expression of CCL2 and adhesion molecules of human proximal tubular epithelial cells through MAPK signaling pathways.
Ho AW; Wong CK; Lam CW
Immunobiology; 2008; 213(7):533-44. PubMed ID: 18656701
[TBL] [Abstract][Full Text] [Related]
11. [Extract of Serenoa repens in the treatment of benign prostatic hyperplasia and lower urinary tract symptoms].
Amdii RE; Al' Shukri AS
Urologiia; 2018 May; (2):114-120. PubMed ID: 29901305
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological effects of the lipidosterolic extract of Serenoa repens (Permixon) on rat prostate hyperplasia induced by hyperprolactinemia: comparison with finasteride.
Van Coppenolle F; Le Bourhis X; Carpentier F; Delaby G; Cousse H; Raynaud JP; Dupouy JP; Prevarskaya N
Prostate; 2000 Apr; 43(1):49-58. PubMed ID: 10725865
[TBL] [Abstract][Full Text] [Related]
13. Relaxin inhibits early steps in vascular inflammation.
Brecht A; Bartsch C; Baumann G; Stangl K; Dschietzig T
Regul Pept; 2011 Jan; 166(1-3):76-82. PubMed ID: 20851151
[TBL] [Abstract][Full Text] [Related]
14. Lipido-sterolic extract of Serenoa repens (LSESr, Permixon) treatment affects human prostate cancer cell membrane organization.
Petrangeli E; Lenti L; Buchetti B; Chinzari P; Sale P; Salvatori L; Ravenna L; Lococo E; Morgante E; Russo A; Frati L; Di Silverio F; Russo MA
J Cell Physiol; 2009 Apr; 219(1):69-76. PubMed ID: 19067321
[TBL] [Abstract][Full Text] [Related]
15. Effect of Serenoa repens extract (Permixon) on estradiol/testosterone-induced experimental prostate enlargement in the rat.
Paubert-Braquet M; Richardson FO; Servent-Saez N; Gordon WC; Monge MC; Bazan NG; Authie D; Braquet P
Pharmacol Res; 1996; 34(3-4):171-9. PubMed ID: 9051712
[TBL] [Abstract][Full Text] [Related]
16. Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, Permixon in benign prostatic hyperplasia.
Vacherot F; Azzouz M; Gil-Diez-De-Medina S; Colombel M; De La Taille A; Lefrère Belda MA; Abbou CC; Raynaud JP; Chopin DK
Prostate; 2000 Nov; 45(3):259-66. PubMed ID: 11074529
[TBL] [Abstract][Full Text] [Related]
17. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia.
Di Silverio F; Monti S; Sciarra A; Varasano PA; Martini C; Lanzara S; D'Eramo G; Di Nicola S; Toscano V
Prostate; 1998 Oct; 37(2):77-83. PubMed ID: 9759701
[TBL] [Abstract][Full Text] [Related]
18. Effect of antiallergic herbal agents on chloride channel-3 and immune microenvironment in nasal mucosal epithelia of allergic rhinitis rabbits.
Wang LF; Xu LJ; Guo FH; Wang LN; Shen XH
Chin Med J (Engl); 2010 Apr; 123(8):1034-8. PubMed ID: 20497710
[TBL] [Abstract][Full Text] [Related]
19. Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action.
Buck AC
J Urol; 2004 Nov; 172(5 Pt 1):1792-9. PubMed ID: 15540722
[TBL] [Abstract][Full Text] [Related]
20. The influence of garlic (Allium sativum) extract on interleukin 1alpha-induced expression of endothelial intercellular adhesion molecule-1 and vascular cell adhesion molecule-1.
Rassoul F; Salvetter J; Reissig D; Schneider W; Thiery J; Richter V
Phytomedicine; 2006 Mar; 13(4):230-5. PubMed ID: 16492524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
